{"id":"sitagliptin-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":"5-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"<0.1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":{"setId":"2f635b36-e86a-4e53-8eaf-589917b5f342","title":"ZITUVIMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [ZYDUS PHARMACEUTICALS USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon levels. Metformin is a biguanide that decreases hepatic glucose production and increases peripheral glucose uptake and insulin sensitivity. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:19.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05367063","phase":"PHASE4","title":"Canagliflozin and Myocardial Fibrosis","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-01-05","conditions":"Type 2 Diabetes, Cardiovascular Risk","enrollment":45},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT07172269","phase":"NA","title":"Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Mais Qais Hbeeb","startDate":"2024-09-15","conditions":"Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT06952231","phase":"PHASE3","title":"Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-05-21","conditions":"Diabetes Mellitus","enrollment":50},{"nctId":"NCT04271189","phase":"PHASE3","title":"Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Newly Diagnosed Type 2 Diabetes","enrollment":108},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT02512523","phase":"PHASE4","title":"Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-08-27","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT04017832","phase":"PHASE3","title":"A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1441},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06515652","phase":"NA","title":"To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome","status":"RECRUITING","sponsor":"Hamdard University","startDate":"2023-09-01","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06233201","phase":"PHASE1","title":"Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-06-04","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT06233240","phase":"PHASE1","title":"Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-04-30","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT06204107","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-11-21","conditions":"Type 2 Diabetes Mellitus","enrollment":28},{"nctId":"NCT06147518","phase":"NA","title":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-20","conditions":"Compensated Cirrhosis, Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT06124495","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-13","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124547","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-16","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT06124560","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-10-28","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124573","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-11-07","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT05798715","phase":"PHASE1","title":"Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-11-29","conditions":"Healthy","enrollment":30},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT05549570","phase":"PHASE1","title":"Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2017-10-22","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT05549583","phase":"PHASE1","title":"Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2018-04-15","conditions":"Bioequivalence, Type 2 Diabetes","enrollment":26},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT05480007","phase":"NA","title":"Non-alcoholic Fatty Liver Disease and Its Treatment","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2011-01-30","conditions":"NAFLD","enrollment":68},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05214235","phase":"","title":"A Clinical Study on the Effect of Hypoglycemic Drugs on the Prognosis of Spinal Surgery in Diabetic Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-02-07","conditions":"Diabetes Mellitus, Spinal Diseases","enrollment":124},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05167513","phase":"PHASE4","title":"Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2021-01-01","conditions":"Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin","enrollment":188},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT03659461","phase":"NA","title":"Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2017-10-01","conditions":"Type 2 Diabetes Mellitus, PreDiabetes","enrollment":174},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT05032001","phase":"NA","title":"ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT","status":"UNKNOWN","sponsor":"Metabolic Research Unit","startDate":"2021-08-01","conditions":"Abdominal Obesity, Type 2 Diabetes","enrollment":30},{"nctId":"NCT05035849","phase":"NA","title":"Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2020-01-30","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT04916093","phase":"PHASE4","title":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT04877106","phase":"PHASE1","title":"Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2018-04-07","conditions":"Healthy Subjects","enrollment":48},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":190},{"nctId":"NCT04268563","phase":"PHASE1, PHASE2","title":"Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-10","conditions":"Polycystic Ovary Syndrome, Infertility, ART","enrollment":80},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT03061214","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":868},{"nctId":"NCT03359590","phase":"PHASE2","title":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2018-03-21","conditions":"Pharmacological Action","enrollment":20},{"nctId":"NCT00860288","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1988},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT04298684","phase":"PHASE4","title":"Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Guadeloupe","startDate":"2021-01-01","conditions":"Diabetes Mellitus, Type 2, Thyroid Nodule (Benign)","enrollment":90},{"nctId":"NCT01490918","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":165},{"nctId":"NCT03927170","phase":"PHASE1","title":"Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2019-05-02","conditions":"Healthy","enrollment":25},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT01140438","phase":"NA","title":"Treatment of Latent Autoimmune Diabetes of the Adult","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2009-03","conditions":"Diabetes","enrollment":64},{"nctId":"NCT03267576","phase":"PHASE4","title":"An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT00961857","phase":"PHASE1","title":"A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12-01","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02111096","phase":"PHASE2","title":"A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT03813316","phase":"PHASE4","title":"Approaches To Therapy Escalation In T2D","status":"WITHDRAWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2019-05-01","conditions":"Type2 Diabetes","enrollment":""},{"nctId":"NCT02743260","phase":"PHASE4","title":"Drug Transporter Interaction Study PHENTRA_2015_KPUK","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2016-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT01930188","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1231},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT03851341","phase":"PHASE1","title":"Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2019-01-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT01336322","phase":"PHASE2","title":"Metformin and Sitagliptin in Women With Previous Gestational Diabetes","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2011-05","conditions":"Pre-diabetes","enrollment":40},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02256189","phase":"PHASE4","title":"Sitagliptin and Glucagon Counterregulation","status":"COMPLETED","sponsor":"Lund University","startDate":"2015-04","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01907854","phase":"PHASE4","title":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":407},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233}],"_emaApprovals":[],"_faersSignals":[{"count":23,"reaction":"NAUSEA"},{"count":19,"reaction":"DIABETIC KETOACIDOSIS"},{"count":18,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":18,"reaction":"VOMITING"},{"count":17,"reaction":"DIARRHOEA"},{"count":16,"reaction":"ACUTE KIDNEY INJURY"},{"count":15,"reaction":"DRUG INEFFECTIVE"},{"count":14,"reaction":"ANAEMIA"},{"count":12,"reaction":"LACTIC ACIDOSIS"},{"count":11,"reaction":"HYPERKALAEMIA"}],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sitagliptin + Metformin = Janumet","janumet","MK0431A","Janumet™","Sitadin M"],"phase":"marketed","status":"active","brandName":"Sitagliptin + Metformin","genericName":"Sitagliptin + Metformin","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}